NCT04820621View on ClinicalTrials.gov

Study of the Influence of Liver Function on Blood Concentrations of Runcaciguat in Participants With Different Degrees of Liver Impairment

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

April 7, 2021

Primary Completion Date

July 1, 2021

Study Completion Date

July 1, 2021

Conditions
Chronic Kidney Disease
Interventions
DRUG

Runcaciguat (BAY1101042)

Given as 1 x 15 mg modified release \[MR\] tablet

Trial Locations (1)

24105

CRS Clinical-Research-Services Kiel GmbH, Kiel

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY